Terms: = Lymphoma AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
7 results:
1. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
[TBL] [Abstract] [Full Text] [Related]
2. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor.
De Pascale M; Bissegger L; Tarantelli C; Beaufils F; Prescimone A; Mohamed Seid Hedad H; Kayali O; Orbegozo C; Raguž L; Schaefer T; Hebeisen P; Bertoni F; Wymann MP; Borsari C
Eur J Med Chem; 2023 Feb; 248():115038. PubMed ID: 36634458
[TBL] [Abstract] [Full Text] [Related]
3. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract] [Full Text] [Related]
4. treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract] [Full Text] [Related]
5. Mechanisms of activity of the torc1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract] [Full Text] [Related]
6. Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.
Dal Col J; Mastorci K; Faè DA; Muraro E; Martorelli D; Inghirami G; Dolcetti R
Cancer Res; 2012 Apr; 72(7):1825-35. PubMed ID: 22311672
[TBL] [Abstract] [Full Text] [Related]
7. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract] [Full Text] [Related]
